ABX-1431 is primarily investigated for its potential therapeutic applications in the field of neurology and mental health. It is a selective inhibitor of monoacylglycerol lipase (MAGL), an enzyme that plays a crucial role in the breakdown of endocannabinoids in the brain. By inhibiting MAGL, ABX-1431 increases the levels of endocannabinoids, which may help regulate mood, reduce anxiety, and alleviate symptoms of neurological disorders such as Parkinson's disease, multiple sclerosis, and neuropathic pain. Additionally, it is being studied for its potential neuroprotective effects, which could be beneficial in conditions involving neurodegeneration or brain injury. Research is ongoing to explore its efficacy and safety in clinical settings.